Xtant Medical Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $40.82M
- P/E (TTM)
- –
- Dividend yield
- –
About Xtant Medical
Surgical & Medical Instruments & Apparatus, SIC 3841
Xtant Medical Holdings, Inc. develops, manufactures, and markets orthobiologics and spinal implant fixation systems designed to facilitate spinal fusion in degenerative, deformity, and complex spine surgeries. Its orthobiologics offerings include demineralized bone matrices, viable bone allografts, synthetic bone grafts, amniotic membranes, and surgical collagen powders used in spine, trauma, foot and ankle, sports medicine, joint, and wound care applications. Its spinal implant line comprises cervical plating systems, occipito-cervico-thoracic hardware, thoracolumbar pedicle screw systems, sacroiliac joint fusion devices, and interbody spacers made from titanium and PEEK materials. The company supplies these solutions to orthopedic spine surgeons and neurosurgeons.
The company operates primarily in the United States and distributes products through an extensive sales channel comprising more than 670 independent sales agents and stocking agents, along with direct sales personnel. It also accesses integrated delivery networks and hospitals via contracts with major national group purchasing organizations. Internationally, it sells products through stocking distribution partners in Europe, Canada, Mexico, South America, and selected Pacific region countries. Xtant Medical Holdings is headquartered in Belgrade, Montana.
Summary of the business section of Xtant Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Xtant Medical Holdings, Inc.
- Founded
- 2006
- Headquarters
- Belgrade, MT
- Address
- 664 Cruiser Lane 59714
- Phone
- (406) 388-0480
- Website
- xtantmedical.com
- Employees
- 151, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Minneapolis, Minnesota
Stock & identifiers
- Ticker
- XTNT
- Exchange
- NYSE
- Shares outstanding
- 140M, Aug 7, 2026
- Public float
- $45.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Feb 14, 2018; 1-for-10 reverse, Jul 28, 2014; 1-for-10 reverse, Jul 28, 2014
- SEC CIK
- 1453593
- CUSIP
- 98420P308
- ISIN
- US98420P3082
- LEI
- 549300JOU6AK8387EW77
- EIN
- 20-5313323
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sean E. Browne | President and CEO, Director | 3,114,669 |
| Mark A. Schallenberger | Chief Operating Officer | 1,106,087 |
| Scott C. Neils | CFO and Assistant Secretary | 1,243,381 |
| Abhinav Jain | Director | 373,745 |
| John K. Bakewell | Director | 1,129,633 |
| Stavros G. Vizirgianakis | Director | 7,838,845 |
| Jonn R. Beeson | Director | 1,748,408 |
| Tyler Lipschultz | Director | 373,745 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.35M | $1.65M | $1.02M | $119 | – |
| FY2025 Peo | $1.35M | $1.65M | $1.02M | $119 | – |
| FY2024 | $2.46M | $151.24K | $997.72K | $67 | – |
| FY2024 Peo | $2.46M | $151.24K | $997.72K | $67 | – |
| FY2023 | $1.71M | $2.37M | $1.06M | $171 | – |
| FY2023 Peo | $1.71M | $2.37M | $1.06M | $171 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of December 31, 2025, we had 151 employees, all of whom were full time employees, and of whom 64 were in operations, 28 were in sales”
Corporate history
Events identified from SEC filings